Practice Guideline

. 2024 Jul;51(9):2706-2732.

doi: 10.1007/s00259-024-06696-9. Epub 2024 May 14.

Joint EANM-SNMMI guideline on the role of 2-[¹⁸F]FDG PET/CT in no special type breast cancer : (endorsed by the ACR, ESSO, ESTRO, EUSOBI/ESR, and EUSOMA)

Sofia C Vaz^{1

2}, John Patrick Pilkington Woll³, Fatima Cardoso⁴, David Groheux^{5

6

7}, Gary J R Cook^{8

9

10}, Gary A Ulaner^{11

12}, Heather Jacene^{13

14}, Isabel T Rubio¹⁵, Jan W Schoones¹⁶, Marie-Jeanne Vrancken Peeters^{17

18}, Philip Poortmans^{19

20}, Ritse M Mann²¹, Stephanie L Graff^{22

23}, Elizabeth H Dibble²⁴, Lioe-Fee de Geus-Oei^{25

26

27}

Affiliations

¹ Nuclear Medicine-Radiopharmacology, Champalimaud Clinical Center, Champalimaud Foundation, Lisbon, Portugal. sofia.vaz@fundacaochampalimaud.pt.
² Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands. sofia.vaz@fundacaochampalimaud.pt.
³ PET-CT Department, Clinica Delgado AUNA, Lima, Peru.
⁴ Breast Unit, Champalimaud Clinical Center, Champalimaud Foundation, Lisbon, Portugal.
⁵ Nuclear Medicine Department, Saint-Louis Hospital, Paris, France.
⁶ University Paris-Diderot, INSERM U976, Paris, France.
⁷ Centre d'Imagerie Radio-Isotopique (CIRI), La Rochelle, France.
⁸ Department of Cancer Imaging, King's College London, London, UK.
⁹ King's College London and Guy's & St Thomas' PET Centre, London, UK.
¹⁰ School of Biomedical Engineering and Imaging Sciences, King's College London, London, UK.
¹¹ Molecular Imaging and Therapy, Hoag Family Cancer Institute, Newport Beach, CA, USA.
¹² University of Southern California, Los Angeles, CA, USA.
¹³ Dana-Farber Cancer Institute/Brigham and Women's Hospital, Boston, MA, USA.
¹⁴ Harvard Medical School, Boston, MA, USA.
¹⁵ Breast Surgical Oncology, Clinica Universidad de Navarra, Madrid, Cancer Center Clinica Universidad de Navarra, Navarra, Spain.
¹⁶ Directorate of Research Policy, Leiden University Medical Center, Leiden, The Netherlands.
¹⁷ Department of Surgical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
¹⁸ Department of Surgery, Amsterdam University Medical Center, Amsterdam, The Netherlands.
¹⁹ Department of Radiation Oncology, Iridium Netwerk, Antwerp, Belgium.
²⁰ University of Antwerp, Wilrijk, Antwerp, Belgium.
²¹ Radiology Department, RadboudUMC, Nijmegen, The Netherlands.
²² Lifespan Cancer Institute, Providence, Rhode Island, USA.
²³ Legorreta Cancer Center at Brown University, Providence, Rhode Island, USA.
²⁴ Department of Diagnostic Imaging, The Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA. edibble@lifespan.org.
²⁵ Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands. l.f.de_geus-oei@lumc.nl.
²⁶ Biomedical Photonic Imaging Group, University of Twente, Enschede, The Netherlands. l.f.de_geus-oei@lumc.nl.
²⁷ Department of Radiation Science & Technology, Technical University of Delft, Delft, The Netherlands. l.f.de_geus-oei@lumc.nl.

PMID: 38740576
PMCID: PMC11224102
DOI: 10.1007/s00259-024-06696-9

Practice Guideline

Joint EANM-SNMMI guideline on the role of 2-[¹⁸F]FDG PET/CT in no special type breast cancer : (endorsed by the ACR, ESSO, ESTRO, EUSOBI/ESR, and EUSOMA)

Sofia C Vaz et al. Eur J Nucl Med Mol Imaging. 2024 Jul.

. 2024 Jul;51(9):2706-2732.

doi: 10.1007/s00259-024-06696-9. Epub 2024 May 14.

Authors

Affiliations

¹ Nuclear Medicine-Radiopharmacology, Champalimaud Clinical Center, Champalimaud Foundation, Lisbon, Portugal. sofia.vaz@fundacaochampalimaud.pt.
² Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands. sofia.vaz@fundacaochampalimaud.pt.
³ PET-CT Department, Clinica Delgado AUNA, Lima, Peru.
⁴ Breast Unit, Champalimaud Clinical Center, Champalimaud Foundation, Lisbon, Portugal.
⁵ Nuclear Medicine Department, Saint-Louis Hospital, Paris, France.
⁶ University Paris-Diderot, INSERM U976, Paris, France.
⁷ Centre d'Imagerie Radio-Isotopique (CIRI), La Rochelle, France.
⁸ Department of Cancer Imaging, King's College London, London, UK.
⁹ King's College London and Guy's & St Thomas' PET Centre, London, UK.
¹⁰ School of Biomedical Engineering and Imaging Sciences, King's College London, London, UK.
¹¹ Molecular Imaging and Therapy, Hoag Family Cancer Institute, Newport Beach, CA, USA.
¹² University of Southern California, Los Angeles, CA, USA.
¹³ Dana-Farber Cancer Institute/Brigham and Women's Hospital, Boston, MA, USA.
¹⁴ Harvard Medical School, Boston, MA, USA.
¹⁵ Breast Surgical Oncology, Clinica Universidad de Navarra, Madrid, Cancer Center Clinica Universidad de Navarra, Navarra, Spain.
¹⁶ Directorate of Research Policy, Leiden University Medical Center, Leiden, The Netherlands.
¹⁷ Department of Surgical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
¹⁸ Department of Surgery, Amsterdam University Medical Center, Amsterdam, The Netherlands.
¹⁹ Department of Radiation Oncology, Iridium Netwerk, Antwerp, Belgium.
²⁰ University of Antwerp, Wilrijk, Antwerp, Belgium.
²¹ Radiology Department, RadboudUMC, Nijmegen, The Netherlands.
²² Lifespan Cancer Institute, Providence, Rhode Island, USA.
²³ Legorreta Cancer Center at Brown University, Providence, Rhode Island, USA.
²⁴ Department of Diagnostic Imaging, The Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA. edibble@lifespan.org.
²⁵ Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands. l.f.de_geus-oei@lumc.nl.
²⁶ Biomedical Photonic Imaging Group, University of Twente, Enschede, The Netherlands. l.f.de_geus-oei@lumc.nl.
²⁷ Department of Radiation Science & Technology, Technical University of Delft, Delft, The Netherlands. l.f.de_geus-oei@lumc.nl.

PMID: 38740576
PMCID: PMC11224102
DOI: 10.1007/s00259-024-06696-9

Abstract

Introduction: There is much literature about the role of 2-[¹⁸F]FDG PET/CT in patients with breast cancer (BC). However, there exists no international guideline with involvement of the nuclear medicine societies about this subject.

Purpose: To provide an organized, international, state-of-the-art, and multidisciplinary guideline, led by experts of two nuclear medicine societies (EANM and SNMMI) and representation of important societies in the field of BC (ACR, ESSO, ESTRO, EUSOBI/ESR, and EUSOMA).

Methods: Literature review and expert discussion were performed with the aim of collecting updated information regarding the role of 2-[¹⁸F]FDG PET/CT in patients with no special type (NST) BC and summarizing its indications according to scientific evidence. Recommendations were scored according to the National Institute for Health and Care Excellence (NICE) criteria.

Results: Quantitative PET features (SUV, MTV, TLG) are valuable prognostic parameters. In baseline staging, 2-[¹⁸F]FDG PET/CT plays a role from stage IIB through stage IV. When assessing response to therapy, 2-[¹⁸F]FDG PET/CT should be performed on certified scanners, and reported either according to PERCIST, EORTC PET, or EANM immunotherapy response criteria, as appropriate. 2-[¹⁸F]FDG PET/CT may be useful to assess early metabolic response, particularly in non-metastatic triple-negative and HER2+ tumours. 2-[¹⁸F]FDG PET/CT is useful to detect the site and extent of recurrence when conventional imaging methods are equivocal and when there is clinical and/or laboratorial suspicion of relapse. Recent developments are promising.

Conclusion: 2-[¹⁸F]FDG PET/CT is extremely useful in BC management, as supported by extensive evidence of its utility compared to other imaging modalities in several clinical scenarios.

Keywords: 2-[18F]FDG; Breast cancer; EANM; No special type; PET/CT; SNMMI.

PubMed Disclaimer

Conflict of interest statement

Gary Cook: research grant from Breast Cancer Now and he was a previous member of their scientific advisory board.

Gary Ulaner: Consultant/Advisory Board/Research Funding – GE Healthcare, Lantheus, ImaginAb, Point Biopharma

Heather Jacene: Blue Earth Diagnostics, honoraria and research support; Consulting, advanced accelerator applications, spectrum dynamics, royalties: Cambridge University Press; all are not related to the work presented in this manuscript.

Philip Poortmans: medical advisor of Sordina IORT Technologies S.p.A., not related to the work presented in this manuscript.

Ritse Mann: research grants from/with Beckton and Dickinson, Siemens, Bayer Healthcare, Screenpoint medical, Koning, and PA Imaging, and is a medical advisor to Screenpoint, Bayer, Guerbet, and BD. All are unrelated to the work in this manuscript.

Fatima Cardoso: Personal financial interest in form of consultancy role for: Amgen, Astellas/Medivation, AstraZeneca, Celgene, Daiichi-Sankyo, Eisai, GE Oncology, Genentech, Gilead, GlaxoSmithKline, Iqvia, Macrogenics, Medscape, Merck-Sharp, Merus BV, Mylan, Mundipharma, Novartis, Pfizer, Pierre-Fabre, prIME Oncology, Roche, Sanofi, Samsung Bioepis, Seagen, Teva, Touchime.

Institutional financial support for clinical trials from: Amgen, Astra-Zeneca, Boehringer-Ingelheim, Bristol-Myers-Squibb, Daiichi-Sankyo, Eisai, Fresenius GmbH, Genentech, Gilead, GlaxoSmithKline, Ipsen, Incyte, Nektar Therapeutics, Nerviano, Novartis, Macrogenics, Medigene, MedImmune, Merck, Millenium, Pfizer, Pierre-Fabre, Roche, Sanofi-Aventis, Sonus, Tesaro, Tigris, Wilex, Wyeth.

All the other authors declare no conflict of interest.

References

1. Brouwers MC, Kerkvliet K, Spithoff K. The AGREE Reporting Checklist: a tool to improve reporting of clinical practice guidelines. BMJ. 2016;352:i1152. - PMC - PubMed
1. Delgado Bolton RC, Aide N, Colletti PM, Ferrero A, Paez D, Skanjeti A, Giammarile F. EANM guideline on the role of 2-[(18)F]FDG PET/CT in diagnosis, staging, prognostic value, therapy assessment and restaging of ovarian cancer, endorsed by the American College of Nuclear Medicine (ACNM), the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the International Atomic Energy Agency (IAEA) Eur J Nucl Med Mol Imaging. 2021;48:3286–3302. - PubMed
1. Salaün PY, Abgral R, Malard O, Querellou-Lefranc S, Quere G, Wartski M, Coriat R, Hindie E, Taieb D, Tabarin A, et al. Good clinical practice recommendations for the use of PET/CT in oncology. Eur J Nucl Med Mol Imaging. 2020;47:28–50. - PubMed
1. Caresia Aroztegui AP, García Vicente AM, Alvarez Ruiz S, Delgado Bolton RC, Orcajo Rincon J, Garcia Garzon JR, de Arcocha TM, Garcia-Velloso MJ. 18F-FDG PET/CT in breast cancer: evidence-based recommendations in initial staging. Tumour Biol. 2017;39:1010428317728285. - PubMed
1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–249. - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- PubMed Central
- Springer
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Joint EANM-SNMMI guideline on the role of 2-[¹⁸F]FDG PET/CT in no special type breast cancer : (endorsed by the ACR, ESSO, ESTRO, EUSOBI/ESR, and EUSOMA)

Affiliations

Joint EANM-SNMMI guideline on the role of 2-[¹⁸F]FDG PET/CT in no special type breast cancer : (endorsed by the ACR, ESSO, ESTRO, EUSOBI/ESR, and EUSOMA)

Authors

Affiliations

Abstract

Conflict of interest statement

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Research Materials

Miscellaneous